Comparison · NCT00783263-e39e2b03
Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin (10 or 20 mg): Number of Participants Who Reached Their Target LDL-C Level
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg vs Rosuvastatin (10 or 20 mg): Number of Participants Who Reached Their Target LDL-C Level. Trial comparisons, record NCT00783263-e39e2b03. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00783263-e39e2b03
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.594 | 0.527 | 0.657 | wilson | |
| Risk in group 2 | 0.309 | 0.251 | 0.373 | wilson | |
| Risk difference, group 1 minus group 2 | 0.285 | 0.193 | 0.37 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.92 | 1.53 | 2.41 | log | |
| Odds ratio, group 1 over group 2 | 3.27 | 2.2 | 4.85 | log | |
| Number needed to treat, for one more participant with the outcome on Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg than on Rosuvastatin (10 or 20 mg) | 3.51 | 2.7 | 5.19 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rosuvastatin (5 or 10 mg) + Ezetimibe 10 mg | Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks. | 130 | 219 | OG000 |
| Group 2 | Rosuvastatin (10 or 20 mg) | Participants who received rosuvastatin (5 or 10 mg) mg tablets once daily for 4 to 5 weeks then received rosuvastatin (10 or 20 mg) once daily for 6 additional weeks. | 67 | 217 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Reached Their Target LDL-C Level
- Description
Participants were analyzed to evaluate the LDL-C (\<100 mg/dL for moderately high risk patients and high risk patients without AVD and \<70 mg/dL for high risk patients with AVD) lowering efficacy with the addition of ezetimibe 10 mg to (5 or 10 mg) compared with doubling the baseline rosuvastatin (10 or 20 mg), daily for 6 weeks of treatment.
- Time frame
- 6 weeks of treatment
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)
- NCT number
- NCT00783263
- Phases
- PHASE3
- Conditions
- Hypercholesterolemia
- Interventions
- Comparator: rosuvastatin 5 mg + ezetimibe 10 mg, Comparator: rosuvastatin 10 mg, Comparator: rosuvastatin 10 mg + ezetimibe 10 mg, Comparator: rosuvastatin 20 mg
- Lead sponsor
- Organon and Co
- Results first posted
- 2011-09-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00783263?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00783263-e39e2b03